Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Impact of an Alarm Management Protocol on Noise Pollution and Patient Safety in Intensive Care Units

NCT06175091 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-02-08
Last updated
2026-03-10

Condition(s) studied

Intensive Care Unit

Investigational drug(s) / intervention(s)

alarm management left to the discretion of the nurserestrictive alarm use strategy

alarm management left to the discretion of the nurse: alarm management left to the discretion of the nurse in charge of the patient

restrictive alarm use strategy: more restrictive protocol for the use of alarms

Study summary

Resuscitation patients are monitored for various physiological parameters. When these parameters exceed abnormal thresholds, an audible alarm is triggered. Given the complexity of physiological situations and the number of monitored parameters, the number of alarms within an intensive care unit is significant. In the literature, the number ranges from 100 to 350 alarms per patient per day. Among these alarms, 74 to 99% are deemed irrelevant as they provide false or insignificant information. This study will enable to assess the efficacy of a restrictive protocol for managing alarms as a means of rationalizing their use.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient aged ≥ 18 years * Patient admitted to the intensive care unit of the ST-ETIENNE University Hospital * Patient affiliated or entitled to a social security system * Patient having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study or, for patients who are unable to consent due to health condition, a trusted person/family member who has been informed about the study and has who has co-signed, with the investigator, a consent to participate Exclusion Criteria: * Pregnant and nursing women * Persons of legal age under guardianship

Primary outcome measure(s)

  • efficiency criterion: the number of alarms per patient per day — 1 month
    An efficiency criterion: the number of alarms per patient per day
  • A safety criterion: the length of time patients have potentially dangerous heart rate, blood pressure or oxygen saturation values — 1 month
    A safety criterion: the length of time patients have potentially dangerous heart rate, blood pressure or oxygen saturation values.

Trial sites (1)

FacilityCityRegionStatus
CHU de Saint-Etienne Saint-Etienne France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06175091 on ClinicalTrials.gov ↗ ← All trials in France